Asterion Research & Development SPRL
The score of Asterion Research & Development shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets +253 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Asterion Research & Development's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 24 Jul 2026
- Year ended 31 Dec 2024filed on 18 Jun 2025
- Year ended 31 Dec 2023filed on 02 Jul 2024
- Year ended 31 Dec 2022filed on 30 Nov 2023
- Year ended 31 Dec 2021filed on 25 Aug 2022
Asterion Research & Development's financial analysis
- Solvency71.3%sector median: 61.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Asterion Research & Development
Asterion Research & Development's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0682.704.608
- VAT number
- BE0682704608
- Peppol
- Registered · 0208:0682704608 · as of 10 Nov 2026
- Legal form
- SPRL
- Incorporated
- 09 Oct 2017
- Registered office
- 9000 Ghent
- Latest accounts
- 2025 · filed on 24 Jul 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Asterion Research & Development (SPRL) has been based in Ghent since 2017, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of 621,245 € and equity of €1.64m; its revenue is not published. Its solvency stands at 71.3%, above the median of its sector (61.7%).
Companies similar to Asterion Research & Development
Companies in the same business, of comparable size and area, outside its group.
- SECOYA Technologies Manufacture of basic pharmaceutical products Ottignies-Louvain-la-Neuve · balance sheet €2.31m
- Inhatarget Therapeutics Research and experimental development on natural sciences and engineering Charleroi · balance sheet €2.16m
- Galenicap Manufacture of basic pharmaceutical products Ixelles · balance sheet €1.47m
- GRNR Invest Manufacture of basic pharmaceutical products Zemst · balance sheet €2.26m
- Spica Therapeutics Research and experimental development on natural sciences and engineering Antwerp · balance sheet €7.45m
- Celyad Oncology Research and experimental development on natural sciences and engineering Mont-Saint-Guibert · balance sheet €4.03m
- Rejuvenate Biomed Research and experimental development on natural sciences and engineering Diepenbeek · balance sheet €3.45m
- Temmune Therapeutics Manufacture of pharmaceutical preparations Mechelen · balance sheet €3.43m
Frequently asked questions about Asterion Research & Development
What is the revenue of Asterion Research & Development?
Asterion Research & Development files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Asterion Research & Development?
In Belgium, the VAT number is the company number prefixed with BE: BE0682704608 for Asterion Research & Development, if the company is VAT-registered. Its company number (CBE) is 0682.704.608.
Where is the registered office of Asterion Research & Development?
According to the CBE register, the registered office of Asterion Research & Development is in 9000 Ghent.
What is the equity of Asterion Research & Development?
At the close of the 2025 financial year, the equity of Asterion Research & Development amounts to 1,644,281 €, a solvency of 71.3% of total assets.
Who manages Asterion Research & Development?
The register lists 1 active mandates at Asterion Research & Development. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Asterion Research & Development
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →